(17) found that THZ1-tolerant cells partially recovered their sensitivity to 3rd generation EGFR-TKIs and conclude that CDK7 inhibitors could potentially be used as a therapeutic strategy to overcome EMT-associated EGFR-TKI resistance in NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.